Advances of gemcitabin in non-small-cell lung cancer
- VernacularTitle:吉西他滨用于非小细胞肺癌治疗的研究进展
- Author:
Shiying YU
- Publication Type:Journal Article
- Keywords:
gemcitabine;
non-small-cell lung cancer;
chemotherapy
- From:
China Oncology
1998;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Gemcitabine has consistently shown activity as a new agent in non-small-cell lung cancer. In non-small-cell lung cancer, gemcitabine-cisplatin combination response rates range from 31% to 54%, with a median survival time between 8.4 and 15.4 months and a 1-year survival rate between 30% and 59%. The GP schedule has acceptable toxicity. The GP combination can be considered standard therapy for non-small-cell lung cancer. Both 21- and 28-day schedules of GP were equally effective in non-small-cell lung cancer. It is necessary to study by randomized clinical trial, the sequence of cisplatin in GP schedule, the increase of radiosensitivity by gemcitabine, the combination of gemcitabine and other new chemotherapeutic agents.
